Key Highlights

  • Oncology Institute obtained a $75 million term loan facility to fully repay $86 million in 4% senior secured convertible notes.
  • The loan carries an interest rate of at least 3.00% plus 5.75%, with amortization structured as quarterly installments equal to 7.5% of outstanding principal.
  • A minimum net revenue covenant of at least $700 million annually is embedded in the loan agreement.

Loan Facility Details

Oncology Institute entered into a loan agreement with OrbiMed Opportunities (CA) V LLC serving as the lead lender. The facility, aggregating a principal amount of $75 million, was drawn in full at closing, delivering immediate capital to support the company’s debt restructuring strategy. The new financing replaces higher‑cost convertible notes with a more predictable repayment schedule.

Interest and Repayment Terms

The loan bears interest at a rate of at least 3.00% plus 5.75%, indexed to an appropriate overnight financing benchmark. The loan matures in accordance with the terms set forth in the agreement, with standard acceleration provisions applicable upon default.

Debt Refinancing Impact

Proceeds from the term loan, together with existing cash balances, were directed to retire $86 million of 4% senior secured convertible notes. This refinancing reduces near‑term debt obligations, extends the overall maturity profile, and removes the risk of dilution that could arise from the conversion of the former notes.

Warrant Issuance

In conjunction with the refinancing, Oncology Institute issued 10,025,535 warrants to Deerfield Partners. The warrants were issued under a private placement exemption and did not generate additional capital for the company.

Financial Covenants

The loan agreement incorporates a covenant requiring a minimum net revenue of at least $700 million each year, effective from a defined start date and applying to each subsequent twelve‑month interval. Additional covenants restrict the issuance of further indebtedness, dividend payments, and the sale of material assets, thereby protecting lender interests.

Security and Guarantees

The loan is secured by a first‑priority lien on substantially all assets of Oncology Institute and its subsidiaries. Certain direct and indirect subsidiaries have provided guarantees, reinforcing the collateral package.

Market and Sector Implications

This refinancing strengthens Oncology Institute’s balance sheet by lowering financing costs and extending debt maturities, a move that may be viewed positively by investors focused on specialty healthcare providers. The sector will be attentive to the company’s ability to meet the revenue covenant and to the potential exercise of the warrants, which could influence future equity composition.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.